Kymriah

EXUMA Biotech is focused on developing a Chimeric Antigen Receptor (CAR)-T cell product for liquid and solid tumors. Chairman and CEO Dr. Greg Frost spoke with Benzinga about patient access to CAR-T therapies, the technology behind the company's two tumor platforms and the impact the...